Účinnost lenalidomidu u vzácných krevních chorob: u histiocytózy z Langerhansových buněk, multicentrické Castlemanovy choroby, POEMS syndromu, Erdheimovy-Chesterovy choroby a angiomatózy. Popis případů a přehled literatury

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis
Authors

ADAM Zdeněk POUR Luděk KREJČÍ Marta ZAHRADOVÁ Lenka SZTURZ Petr KOUKALOVÁ R. ŘEHÁK Zdeněk NEBESKÝ Tomáš HÁJEK Roman KRÁL Zdeněk MAYER Jiří

Year of publication 2012
Type Article in Periodical
Magazine / Source Vnitřní lékařství
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords lenalidomide; thalidomide; cladribin; anakinra; Langerhans cell histiocytosis; Erdheim-Chester disease; Castleman disease; POEMS syndrome; angiomatosis
Attached files
Description We observed an excellent effect of lenalidomide in multifocal aggressive, repeatedly relapsing Langerhans cell histiocytosis where it led to complete remission. We showed an effect of lenalidomide in Langerhans cell histiocytosis and in Castleman disease. The treatment led to regression of brain infiltrates in a patient with Erdheim-Chester disease. A dose of 10 mg of lenalidomide daily in combination with 50 mg of thalidomide stabilized a course of angiomatosis. Lenalidomide did not deliver the required treatment response in a patient with POEMS syndrome and multiple previous therapies.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info